Opus Genetics Announces New Additions to Its Leadership Team

Opus Genetics Announces New Additions to Its Leadership Team

July 26, 2022

Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases, revealed the new appointments of Vikram Arora, PhD, DABT, as Vice President of Non-Clinical Development; Erin O’Neil, MD, as Vice President of Clinical Development; and Sarah Tuller, JD, RAC, as Vice President of Regulatory Affairs and Medical Writing.

While Drs. O'Neil and Tuller will report to Opus Chief Development Officer Jennifer Hunt, Dr. Arora will report to Opus Chief Scientific Officer Ash Jayagopal, PhD.

Dr. Arora has more than 20 years of pharmacology and toxicology research and development expertise, ranging from early drug discovery through nonclinical programs that enable INDs, to assisting international regulatory filings for commercial therapies including Xembify, Prolastin-C, and HyperRAB.

Dr. Arora joins Opus after serving in a leadership position for 11 years at Grifols, where he oversaw initiatives involving late-stage discovery research, pharmacology/toxicology, pharmacokinetics, and viral safety for candidates in the pipeline.

At the moment, Dr. O'Neil works as an attending ophthalmologist at the Children's Hospital of Philadelphia's (CHOP) Center for Inherited Retinal Degenerations and Ophthalmic Genetics, where she also has a clinical connection.

She is responsible for managing the care of young patients with retinal degenerations and ocular genetic disease presentations in her position. The Diana Davis Spencer Clinical Fellowship Award was given to Dr. O'Neil for her work as a principal investigator on a Foundation Fighting Blindness trial that optimized gene therapy for choroideremia.

Ms. Tuller brings over 20 years of expertise in regulatory strategy and operations, working with a variety of clinical and commercial-stage products for a wide spectrum of therapeutic indications, including various initiatives for rare diseases. Avonex Pen in relapsing MS, Phoslyra in ESRD, and Portrazza in metastatic, squamous NSCLC are just a few of the successful IND, NDA, MAA, and BLA applications she has directed or participated in.